-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text | plus one
On July 27, the official website of CDE showed that the smeglutide injection of Jiuyuan Gene was applied for clinical application
Semaglutide is a new long-acting glucagon-like peptide-1 (GLP-1) analogue of Novo Nordisk
Smeglutide is Novo Nordisk's drug with the highest sales share.
The CDE patent information registration platform shows that Novo Nordisk's smeglutide sequence structure patent and use patent expire in March 2026 in China
Nine gene is a member of the company Hangzhou East China Pharmaceutical Group Holdings Limited
In the field of diabetes, in addition to semaglutide, Huadong Medicine has also deployed the GLP-1 receptor agonist liraglutide.
However, with Eli Lilly's dual-target hypoglycemic drug Tirzepatide head-to-head phase 3 clinical success of semaglutide, the future hypoglycemic drug market may shift to multi-target hypoglycemic drugs
In this field, Huadong Medicine has also obtained an early pipeline through introduction + acquisition: In June 2021, it introduced the Japanese SCOHIA PHARMA, Inc.
